Nanna Lüneborg

Nanna has been a Member of the Board since 2023. She is currently General Partner at Forbion with prior experience atApposite Capital and Novo Ventures, one of the largest healthcare investors globally, where Nanna was a key member of the European deal team focusing on late-stage biopharma investments across Europe.

Nanna has previously served on the Board of Directors of publicly traded and privately held companies, including Lava Therapeutics (LVTX), Numab (private), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private).

In addition to being on the Noema board, Nanna is currently on the board of F2G, BioInvent and Inversago Pharma, as well as being a board observer in Numab Therapeutics.

Nanna has a PhD in Neuroscience from University College London, an MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford.